Fig. 3
From: Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
Illustration of combination therapy of cisplatin and RSK inhibitors. Cisplatin causes DNA damage to cell resulting in p53 activation which in turn inhibits pro-survival signals that regress caspase activation. Inhibition of RSK by cisplatin and RSK inhibitors result in inhibition of pro-apoptotic signals there by increasing caspase activation leading to apoptosis. Combination therapy with cisplatin along with RSK inhibitors may result in better inhibition of cancer progression